An Observational Study on Epithelioid Sarcoma

Italian Sarcoma Group100 enrolled

Overview

Prospective Italian study aimed to provide a description of the population affected by Epithelioid Sarcoma (ES)

The present prospective national study aims to provide a description of the population affected by ES, an insight into the natural history of the disease and an answer some on the outstanding questions on its management. Also, it will focus on enhancing any differences between the two ES variants (classical-type and proximal-type) in order gain a better understanding of the disease, tailor the treatment and lastly improve outcome.

Study Type

OBSERVATIONAL

Enrollment

100

Conditions

Epithelioid Sarcoma

Interventions

Treatment for Epitheloid SarcomaOTHER

Treatment Epitheloid Sarcoma according the disease guideline

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion criteria 1. Histological diagnosis of epithelioid sarcoma according to 2014 World Health Organization (WHO) classification, performed on biopsy or surgical specimen 2. Signed informed consent 3. Adequate patient compliance to treatment or follow up 4. No age limit Exclusion criteria 1. Other malignancies within past 5 years, with exception of carcinoma in situ of the cervix and basocellular skin cancers treated with eradicating intent 2. Impossibility to ensure adequate compliance

Locations (11)

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori - IRST

Meldola, FC, Italy

RECRUITING

Istituto Europeo di Oncologia

Milan, MI, Italy

RECRUITING

Outcomes

Primary Outcomes

Type of treatment given to patients with ES

Number of chemotherapy treatment received patients affected by ES

Time frame: From diagnosis until the date of death from any cause assessed up to 60 months

Secondary Outcomes

Radiotherapy treatments

Number of patients affected by localized ES who received radiotherapy

Time frame: From the time of diagnosis and then every 6 months up to 60 months

Chemotherapy treatments

Number of patients affected by localized ES who received chemotherapy

Time frame: From the time of diagnosis and then every 6 months up to 60 months

Predictive biomarkers for response

Tumor biomarkers expression in tumor tissue of patients affected by ES

Time frame: At time of diagnosis and at the time of any progression where a biopsy is performed up to 60 months

Central Contacts

Annamaria Frezza, MD

CONTACT

003902390 annamaria.frezza@istitutotumori.mi.it

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.